<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03190044</url>
  </required_header>
  <id_info>
    <org_study_id>ParMig Study</org_study_id>
    <nct_id>NCT03190044</nct_id>
  </id_info>
  <brief_title>Magnesium, Partenium, Andrographis, Co-enzyme Q10 and Riboflavin (PACR) in Migraine Prophylaxis</brief_title>
  <acronym>ParMig</acronym>
  <official_title>A Fixed Combination of Magnesium, Partenium, Andrographis, Co-enzyme Q10 and Riboflavin (PACR) as Prophylactic Treatment for Migraine: a Randomized Controlled Double Blind Study (ParMig Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gianluca Coppola</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Francesco Pierelli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Migraine is a highly disabling disorder that affects hundreds of millions of people around
      the world. Yet, a little number of prophylactic treatments are available still now. The
      limited number of available drugs leads to a wide use of nutraceutical compounds in migraine
      therapy. To improve the efficacy, some of these nutraceuticals were combined. So far, we do
      not know if these combinations are really more effective than the single compounds alone, or
      an anti-synergic effect could be present because of a reciprocal antagonism of effects. For
      this reason, we decided to test the efficacy of a fixed combination of magnesium, partenium,
      andrographis, co-enzyme Q10 and riboflavin (PACR) as prophylactic treatment for migraine in a
      randomized controlled double blind study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Care Provider)</masking>
    <masking_description>Placebo and 'verum' pills have the similar shape and colour.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Migraine improvement in terms of responder rate</measure>
    <time_frame>3 months</time_frame>
    <description>Number of subjects that at least have a reduction of 50% in terms of migraine frequency</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Migraine improvement in terms of frequencies</measure>
    <time_frame>3 months</time_frame>
    <description>reduction of migraine in terms of number of attacks, headache days, and number of analgesics per month.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>Migraineurs (verum)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One pill per day of PACR: magnesium 281,25 mg; partenium 150 mg (partenolides 1200mcg); andrographis 100 mg (andrographolides 10 mg); co-enzyme Q10 20 mg; riboflavin 4,8 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Migranineurs (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One pill per day of placebo: Cellulose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PACR</intervention_name>
    <description>Daily assumption of PACR for a 3-month period</description>
    <arm_group_label>Migraineurs (verum)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily assumption of placebo</description>
    <arm_group_label>Migranineurs (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of migraine (with or without aura)

          -  both genders

          -  age between 18 and 65 y.o.

          -  more than 1 year of migraine history

          -  no other headache conditions

          -  a migraine frequency between 2 and 8 per month

        Exclusion Criteria:

          -  Prophylactic treatments in the last 3 months

          -  pregnancy or lactation

          -  other medical conditions that requires a daily drug assumption

          -  intolerance or allergic reactions to some of compounds of the product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cherubino Di Lorenzo, MD, PhD</last_name>
      <phone>+393286783246</phone>
      <email>cherubino.dilorenzo@uniroma1.it</email>
    </contact>
    <contact_backup>
      <last_name>Francesco Pierelli, MD</last_name>
      <email>francesco.pierelli@uniroma1.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <last_update_submitted>June 15, 2017</last_update_submitted>
  <last_update_submitted_qc>June 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Cherubino DI LORENZO</investigator_full_name>
    <investigator_title>Research Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
    <mesh_term>Andrographolide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

